Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
- Citation:
- Blood vol 105 (9) 3420-3427
- Year:
- 2005
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- CA33601, CA04457, CA11789, CA02599, CA77406, CA0796, CA47577, CA47555, CA32291, CA41287, CA03927, CA26806, CA35279, CA12046, CA16450, 33601, CA77440, CA04326, CA08025, CA21060, 31946, CA47559, CA47642, CA77658, CA12449, CA37135, 101140, 16058, CA31983, CA31946, CA47545
- Corr. Author:
- Joseph O. Moore
- Authors:
- Joseph O. Moore Stephen L. George Richard K. Dodge Philip C. Amrein Bayard L. Powell Jonathan E. Kolitz Maria R. Baer Frederick R. Davey Clara D. Bloomfield Richard A. Larson Charles A. Schiffer
- Networks:
- Study
- CALGB-9222
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Clinical Observations, Interventions, and Therapeutic Trials